Potent anti-ischaemic effects of statins in chronic stable angina: Incremental benefit beyond lipid lowering?

European Heart Journal

Volumn 31, Issue 21, 2010, Pages 2650-2659

  Deanfield, John E ^a   Sellier, Phillipe ^b   Thaulow, Erik ^c   Bultas, Jan ^d   Yunis, Carla ^e   Shi, Harry ^e   Buch, Jan ^e   Beckerman, Bruce ^e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HÔPITAL BROUSSAIS   (France)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d CHARLES UNIVERSITY   (Czech Republic)

^e PFIZER INC   (United States)

Author keywords

Combination therapy; Coronary artery disease; Statin; Transient myocardial ischaemia

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS ATORVASTATIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; STABLE ANGINA PECTORIS;

AGED, 80 AND OVER; AMLODIPINE; ANGINA, STABLE; ANTIHYPERTENSIVE AGENTS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ELECTROCARDIOGRAPHY, AMBULATORY; EXERCISE TEST; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PYRROLES; YOUNG ADULT;

EID: 78149318321     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq133     Document Type: Article

References (22)

1. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008;117:1283-1291.
2. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006; 83:456S-460S.
3. Deedwania PC, Carbajal EV. Silent ischemia during daily life is an independent predictor of mortality in stable angina. Circulation 1990;81:748-756.
4. Deanfield JE, Detry JM, Lichtlen PR, Magnani B, Sellier P, Thaulow E. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind Circadian Anti-Ischemia Program in Europe (CAPE Trial). J Am Coll Cardiol 1994;24:1460-1467.
5. Deedwania PC, Carbajal EV. Prevalence and patterns of silent myocardial ischemia during daily life in stable angina patients receiving conventional antianginal drug therapy. Am J Cardiol 1990;65:1090-1096.
6. Deanfield JE, Detry JM, Sellier P, Lichtlen PR, Thaulow E, Bultas J, Brennan C, Young ST, Beckerman B. Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial. J Am Coll Cardiol 2002;40:917-925.
7. Robinson JG. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk. Am J Cardiol 2008;101:1009-1015.
8. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revasculariza-tion Treatment Investigators. N Engl J Med 1999;341:70-76.
9. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-1718.
10. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504.
11. Mason RP, Kubant R, Heeba G, Jacob RF, Day CA, Medlin YS, Funovics P, Malinski T. Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction. Pharm Res 2008;25:1798-1806.
12. Saino A, Pomidossi G, Perondi R, Gregorini L, Rimini A, Alessio P, Zanchetti A, Mancia G. Effects of amlodipine on coronary hemodynamics and vascular responses to sympathetic stimulation in patients with coronary heart disease. J Cardiovasc Pharmacol 1994;24:875-882.
13. Silke B, Verma SP, Zezulka AV, Sharma S, Reynolds G, Jackson NC, Guy S, Taylor SH. Haemodynamic and radionuclide effects of amlodipine in coronary artery disease. Br J Clin Pharmacol 1990;29:437-445.
14. Yeung AC, Vekshtein VI, Krantz DS, Vita JA, Ryan TJ Jr, Ganz P, Selwyn AP. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med 1991;325:1551-1556.
15. Anderson TJ. Prognostic significance of brachial flow-mediated vasodilation. Circulation 2007;115:2373-2375.
16. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008;14:37-44.
17. Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 2004;109(21 Suppl. 1):II42-II48.
18. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-1158. (Pubitemid 36398384)
19. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, on behalf of the Cards Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multi-centre randomised placebo-controlled trial. Lancet 2004;364:685-696.
20. Genser B, Grammer TB, Stojakovic T, Siekmeier R, Maerz W. Effect of HMG CoA reductase inhibitors on low-density lipoprotein cholesterol and C-reactive protein: systemic review and meta-analysis. Int J Clin Pharmacol Ther 2008;46: 497-510.
21. Deanfield JE, Selwyn AP. Character and causes of transient myocardial ischemia during daily life. Implications for treatment of patients with coronary disease. Am J Med 1986;80:18-24.
22. Stamler J, Neaton JD. The Multiple Risk Factor Intervention Trial (MRFIT)\-importance then and now. JAMA 2008;300:1343-1345.